Israel Finds Fourth Pfizer Dose Produces Five-fold Increase in Antibodies, as Country Prepares to Launch Moderna Fourth Shot Trial 04/01/2022 Maayan Hoffman A fourth shot of the Pfizer coronavirus vaccine administered to individuals who received their third shot nearly five months ago produces a five-fold increase in antibodies, according to preliminary results of a first-in-the-world trial being conducted in Israel. The news comes on the same day that the country announced it would launch a trial to […] Continue reading -> As Europe Sees Wave of Seasonal Flu – What are the Risks for ‘Flurona?’ 04/01/2022 Maayan Hoffman The world’s first case of “flurona” – a co-infection with both seasonal influenza and COVID-19 was reported in Israel last week, as the Omicron variant sweeps across the world. Since then, small numbers of people co-infected with both viruses have been identified in other European countries as well, a World Health Organization official in the […] Continue reading -> New Data on Side Effects of Second Pfizer Shot in Children Shows Fewer Adverse Effects than for Teens 04/01/2022 Maayan Hoffman Two new large scale reviews of the effects of the two-dose Pfizer’s mRNA vaccine in children aged 5-11 shows fewer severe effects than in older groups. Tuesday’s report, by the Israeli Health Fund Maccabi covering more than 20,000 children, comes on the heels of a similar US Centers for Disease Control and Prevention (CDC) study […] Continue reading -> Can a Fourth Pfizer Dose Halt the Omicron Wave? Israel will be the First Country to Find Out 03/01/2022 Maayan Hoffman JERUSALEM – Israel once again has placed itself in the middle of the global clinical debate on the medical benefits of a fourth Pfizer shot to slow the Omicron wave, when it became the first country to approve such an injection for all citizens over the age of 60 and healthcare workers. Israeli Prime Minister […] Continue reading -> Second J& J Jab Provides 85% Protection Against Omicron Hospitalization in New South African Study 30/12/2021 Elaine Ruth Fletcher A new South African study shows that a second Johnson & Johnson dose, administered 6-9 months after the initial single-dose vaccine provided 84% protection against hospitalization from the Omicron SARS-CoV2 variant – results that even outperformed those of an earlier South African study looking at effectiveness of the two-dose Pfizer regime in the face of […] Continue reading -> Two Years Into Pandemic WHO Warns of Omicron ‘Tsunami’; Variant Confounds Easy Predictions 29/12/2021 Elaine Ruth Fletcher As the world marks two years since the emergence of the first reports about a “novel coronavirus” circulating in Wuhan China, countries in Europe, North America and elsewhere are facing yet another “tsunami” of infections – this time driven by the highly-infectious Omicron variant, warned WHO Director General Dr. Tedros Adhanom Ghebreyesus. He spoke at […] Continue reading -> ‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Omicron Hospitalizations 40% Lower, New British Study Finds 23/12/2021 Elaine Ruth Fletcher A major new British study has provided encouraging data that people infected with the Omicron variant are 20% less like to visit a hospital and 40% less likely to be admitted overnight than those with the Delta variant. The Imperial College study, published Thursday, looked at everyone with a confirmed infection of either variant in […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Posts navigation Older postsNewer posts
As Europe Sees Wave of Seasonal Flu – What are the Risks for ‘Flurona?’ 04/01/2022 Maayan Hoffman The world’s first case of “flurona” – a co-infection with both seasonal influenza and COVID-19 was reported in Israel last week, as the Omicron variant sweeps across the world. Since then, small numbers of people co-infected with both viruses have been identified in other European countries as well, a World Health Organization official in the […] Continue reading -> New Data on Side Effects of Second Pfizer Shot in Children Shows Fewer Adverse Effects than for Teens 04/01/2022 Maayan Hoffman Two new large scale reviews of the effects of the two-dose Pfizer’s mRNA vaccine in children aged 5-11 shows fewer severe effects than in older groups. Tuesday’s report, by the Israeli Health Fund Maccabi covering more than 20,000 children, comes on the heels of a similar US Centers for Disease Control and Prevention (CDC) study […] Continue reading -> Can a Fourth Pfizer Dose Halt the Omicron Wave? Israel will be the First Country to Find Out 03/01/2022 Maayan Hoffman JERUSALEM – Israel once again has placed itself in the middle of the global clinical debate on the medical benefits of a fourth Pfizer shot to slow the Omicron wave, when it became the first country to approve such an injection for all citizens over the age of 60 and healthcare workers. Israeli Prime Minister […] Continue reading -> Second J& J Jab Provides 85% Protection Against Omicron Hospitalization in New South African Study 30/12/2021 Elaine Ruth Fletcher A new South African study shows that a second Johnson & Johnson dose, administered 6-9 months after the initial single-dose vaccine provided 84% protection against hospitalization from the Omicron SARS-CoV2 variant – results that even outperformed those of an earlier South African study looking at effectiveness of the two-dose Pfizer regime in the face of […] Continue reading -> Two Years Into Pandemic WHO Warns of Omicron ‘Tsunami’; Variant Confounds Easy Predictions 29/12/2021 Elaine Ruth Fletcher As the world marks two years since the emergence of the first reports about a “novel coronavirus” circulating in Wuhan China, countries in Europe, North America and elsewhere are facing yet another “tsunami” of infections – this time driven by the highly-infectious Omicron variant, warned WHO Director General Dr. Tedros Adhanom Ghebreyesus. He spoke at […] Continue reading -> ‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Omicron Hospitalizations 40% Lower, New British Study Finds 23/12/2021 Elaine Ruth Fletcher A major new British study has provided encouraging data that people infected with the Omicron variant are 20% less like to visit a hospital and 40% less likely to be admitted overnight than those with the Delta variant. The Imperial College study, published Thursday, looked at everyone with a confirmed infection of either variant in […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Posts navigation Older postsNewer posts
New Data on Side Effects of Second Pfizer Shot in Children Shows Fewer Adverse Effects than for Teens 04/01/2022 Maayan Hoffman Two new large scale reviews of the effects of the two-dose Pfizer’s mRNA vaccine in children aged 5-11 shows fewer severe effects than in older groups. Tuesday’s report, by the Israeli Health Fund Maccabi covering more than 20,000 children, comes on the heels of a similar US Centers for Disease Control and Prevention (CDC) study […] Continue reading -> Can a Fourth Pfizer Dose Halt the Omicron Wave? Israel will be the First Country to Find Out 03/01/2022 Maayan Hoffman JERUSALEM – Israel once again has placed itself in the middle of the global clinical debate on the medical benefits of a fourth Pfizer shot to slow the Omicron wave, when it became the first country to approve such an injection for all citizens over the age of 60 and healthcare workers. Israeli Prime Minister […] Continue reading -> Second J& J Jab Provides 85% Protection Against Omicron Hospitalization in New South African Study 30/12/2021 Elaine Ruth Fletcher A new South African study shows that a second Johnson & Johnson dose, administered 6-9 months after the initial single-dose vaccine provided 84% protection against hospitalization from the Omicron SARS-CoV2 variant – results that even outperformed those of an earlier South African study looking at effectiveness of the two-dose Pfizer regime in the face of […] Continue reading -> Two Years Into Pandemic WHO Warns of Omicron ‘Tsunami’; Variant Confounds Easy Predictions 29/12/2021 Elaine Ruth Fletcher As the world marks two years since the emergence of the first reports about a “novel coronavirus” circulating in Wuhan China, countries in Europe, North America and elsewhere are facing yet another “tsunami” of infections – this time driven by the highly-infectious Omicron variant, warned WHO Director General Dr. Tedros Adhanom Ghebreyesus. He spoke at […] Continue reading -> ‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Omicron Hospitalizations 40% Lower, New British Study Finds 23/12/2021 Elaine Ruth Fletcher A major new British study has provided encouraging data that people infected with the Omicron variant are 20% less like to visit a hospital and 40% less likely to be admitted overnight than those with the Delta variant. The Imperial College study, published Thursday, looked at everyone with a confirmed infection of either variant in […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Posts navigation Older postsNewer posts
Can a Fourth Pfizer Dose Halt the Omicron Wave? Israel will be the First Country to Find Out 03/01/2022 Maayan Hoffman JERUSALEM – Israel once again has placed itself in the middle of the global clinical debate on the medical benefits of a fourth Pfizer shot to slow the Omicron wave, when it became the first country to approve such an injection for all citizens over the age of 60 and healthcare workers. Israeli Prime Minister […] Continue reading -> Second J& J Jab Provides 85% Protection Against Omicron Hospitalization in New South African Study 30/12/2021 Elaine Ruth Fletcher A new South African study shows that a second Johnson & Johnson dose, administered 6-9 months after the initial single-dose vaccine provided 84% protection against hospitalization from the Omicron SARS-CoV2 variant – results that even outperformed those of an earlier South African study looking at effectiveness of the two-dose Pfizer regime in the face of […] Continue reading -> Two Years Into Pandemic WHO Warns of Omicron ‘Tsunami’; Variant Confounds Easy Predictions 29/12/2021 Elaine Ruth Fletcher As the world marks two years since the emergence of the first reports about a “novel coronavirus” circulating in Wuhan China, countries in Europe, North America and elsewhere are facing yet another “tsunami” of infections – this time driven by the highly-infectious Omicron variant, warned WHO Director General Dr. Tedros Adhanom Ghebreyesus. He spoke at […] Continue reading -> ‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Omicron Hospitalizations 40% Lower, New British Study Finds 23/12/2021 Elaine Ruth Fletcher A major new British study has provided encouraging data that people infected with the Omicron variant are 20% less like to visit a hospital and 40% less likely to be admitted overnight than those with the Delta variant. The Imperial College study, published Thursday, looked at everyone with a confirmed infection of either variant in […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Posts navigation Older postsNewer posts
Second J& J Jab Provides 85% Protection Against Omicron Hospitalization in New South African Study 30/12/2021 Elaine Ruth Fletcher A new South African study shows that a second Johnson & Johnson dose, administered 6-9 months after the initial single-dose vaccine provided 84% protection against hospitalization from the Omicron SARS-CoV2 variant – results that even outperformed those of an earlier South African study looking at effectiveness of the two-dose Pfizer regime in the face of […] Continue reading -> Two Years Into Pandemic WHO Warns of Omicron ‘Tsunami’; Variant Confounds Easy Predictions 29/12/2021 Elaine Ruth Fletcher As the world marks two years since the emergence of the first reports about a “novel coronavirus” circulating in Wuhan China, countries in Europe, North America and elsewhere are facing yet another “tsunami” of infections – this time driven by the highly-infectious Omicron variant, warned WHO Director General Dr. Tedros Adhanom Ghebreyesus. He spoke at […] Continue reading -> ‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Omicron Hospitalizations 40% Lower, New British Study Finds 23/12/2021 Elaine Ruth Fletcher A major new British study has provided encouraging data that people infected with the Omicron variant are 20% less like to visit a hospital and 40% less likely to be admitted overnight than those with the Delta variant. The Imperial College study, published Thursday, looked at everyone with a confirmed infection of either variant in […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Posts navigation Older postsNewer posts
Two Years Into Pandemic WHO Warns of Omicron ‘Tsunami’; Variant Confounds Easy Predictions 29/12/2021 Elaine Ruth Fletcher As the world marks two years since the emergence of the first reports about a “novel coronavirus” circulating in Wuhan China, countries in Europe, North America and elsewhere are facing yet another “tsunami” of infections – this time driven by the highly-infectious Omicron variant, warned WHO Director General Dr. Tedros Adhanom Ghebreyesus. He spoke at […] Continue reading -> ‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Omicron Hospitalizations 40% Lower, New British Study Finds 23/12/2021 Elaine Ruth Fletcher A major new British study has provided encouraging data that people infected with the Omicron variant are 20% less like to visit a hospital and 40% less likely to be admitted overnight than those with the Delta variant. The Imperial College study, published Thursday, looked at everyone with a confirmed infection of either variant in […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Posts navigation Older postsNewer posts
‘Vaccine for World’ Gets Emergency Use Authorization in India; Texas Children’s Hospital Grants Non-Exclusive License to Biological E 28/12/2021 Elaine Ruth Fletcher Vaccine equity advocates see huge potential in India’s decision to grant an emergency use license to CORBEVAX™, an open-license vaccine dubbed “The World’s COVID-19 Vaccine” by its developers at Texas Children’s Hospital and Baylor College of Medicine. The protein sub-unit vaccine, engineered at Baylor’s Center for Vaccine Development (CVD), received the Emergency Use Authorization (EUA) […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Omicron Hospitalizations 40% Lower, New British Study Finds 23/12/2021 Elaine Ruth Fletcher A major new British study has provided encouraging data that people infected with the Omicron variant are 20% less like to visit a hospital and 40% less likely to be admitted overnight than those with the Delta variant. The Imperial College study, published Thursday, looked at everyone with a confirmed infection of either variant in […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Posts navigation Older postsNewer posts
The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> Omicron Hospitalizations 40% Lower, New British Study Finds 23/12/2021 Elaine Ruth Fletcher A major new British study has provided encouraging data that people infected with the Omicron variant are 20% less like to visit a hospital and 40% less likely to be admitted overnight than those with the Delta variant. The Imperial College study, published Thursday, looked at everyone with a confirmed infection of either variant in […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Posts navigation Older postsNewer posts
Omicron Hospitalizations 40% Lower, New British Study Finds 23/12/2021 Elaine Ruth Fletcher A major new British study has provided encouraging data that people infected with the Omicron variant are 20% less like to visit a hospital and 40% less likely to be admitted overnight than those with the Delta variant. The Imperial College study, published Thursday, looked at everyone with a confirmed infection of either variant in […] Continue reading -> US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Posts navigation Older postsNewer posts
US FDA Approves First Two Oral Anti-COVID Treatments: Pfizer’s Paxlovid & Merck’s Molnupiravir 23/12/2021 Zachary Brennan WASHINGTON D.C. (ENDPOINTS News) – The FDA on Thursday authorized another new pill to treat the Omicron variant, this time from Merck. The FDA decision follows upon a decision Wednesday authorizing Pfizer’s Paxlovid oral treatment, which the company said had proved to reduce the relative risk of hospitalization or death by 89% (within three days […] Continue reading -> Posts navigation Older postsNewer posts